Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases

The economic burden of acromegaly in the US has been largely unknown. We describe the prevalence of treatment patterns, complication rates, and associated healthcare utilization and costs of acromegaly in the US. Patients were identified between 1/1/2002 and 12/31/2009 in claims databases. During 1-...

Full description

Saved in:
Bibliographic Details
Published in:Pituitary 2014-08, Vol.17 (4), p.333-341
Main Authors: Broder, M. S., Neary, M. P., Chang, E., Cherepanov, D., Katznelson, L.
Format: Article
Language:English
Subjects:
Acromegaly - complications
Acromegaly - drug therapy
Acromegaly - economics
Adolescent
Adult
Aged
Databases, Factual
Endocrinology
Female
Health Care Costs
Human Physiology
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
United States
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The economic burden of acromegaly in the US has been largely unknown. We describe the prevalence of treatment patterns, complication rates, and associated healthcare utilization and costs of acromegaly in the US. Patients were identified between 1/1/2002 and 12/31/2009 in claims databases. During 1-year after each continuously-enrolled patient’s first acromegaly claim, pharmacy and medical claims were used to estimate outcomes. Regression models were used to adjust outcomes. There were 2,171 acromegaly patients (mean age: 45.3 years; 49.7 % female); 77.8 % received the majority of their care from non-endocrinologists. Pharmacologic treatment was used by 30.8 % of patients: octreotide-LAR in 18.6 %, dopamine agonists in 9.8 %, short-acting octreotide in 4.7 %, pegvisomant in 4.1 %, and lanreotide in 1.2 %; 56 % had biochemical monitoring. Comorbidities were common, ranging from 6.6 % (colon neoplasms) to 25.6 % (musculoskeletal abnormalities). Mean healthcare costs were $24,900. Adjusted analyses indicated comorbidities increased the odds of hospitalization: by 76 % for musculoskeletal abnormalities; 193 % for cardiovascular abnormalities; and 56 % for sleep apnea ( p  
ISSN:1386-341X
1573-7403
DOI:10.1007/s11102-013-0506-0